Anti-EGFR therapy: Towards a «made-to-order» targeting of hepatocellular carcinoma;Thérapie anti-EGFR: Vers un ciblage «à la carte» du carcinome hépatocellulaire

Gastroenterologie Clinique et Biologique

Volumn 30, Issue 10, 2006, Pages 1133-1135

  Fartoux, Lætitia ^a,b,c   Desbois Mouthon, Christèle ^b,c   Poupon, Raoul ^a,b,c   Rosmorduc, Olivier ^a,b,c,d  

^a HÔPITAL SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; GEMCITABINE; OXALIPLATIN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; META ANALYSIS; METASTASIS; MUTATION; PROGNOSIS; SYSTEMATIC REVIEW; TUMOR GROWTH;

EID: 33750583241     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(06)73490-x     Document Type: Editorial

References (27)

1. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Review. Gastroenterology 2001;120:726-48.
2. Chevret S, Trinchet JC, Mathieu M, Rachod AA, Beaugrand M, Chastang C, et al. A new pronostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 1999;31:133-41.
3. Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. J Hepatol 2003;38:S136-49.
4. Okuda K. Where we go with hepatocellular carcinoma: past, present, and future perspectives. J Hepatobiliary Pancreat Surg 2002;9:683-5.
5. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 2005;25:212-25.
6. Thorgeirsson S, Grisham J. Molecular pathogenesis of hepatocellular carcinoma. Nat Genet 2002;31:339-46.
7. Morimitsu Y, Hsia CC, Kojiro M. Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-alpha and its receptor in the different areas of tumor. Hum Pathol 1995;26:1126-32.
8. Nalesnik MA, Lee RG, Carr BI. Transforming growth factor-alpha in hepatocellular carcinomas and adjacent hepatic parenchyma. Hum Pathol 1998;29:228-34.
9. Harada K, Shiota G, Kawasaki H. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver 1999;19:318-25.
10. Chung YH, Kim JA, Song BC. Expression of transforming growth factor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma. Cancer 2000;89:977-82.
11. Lee GH, Merlino G, Fausto N. Development of liver tumors in transforming growth factor alpha transgenic mice. Cancer Res 1992;52:5162-70.
12. Jakubczak JL, Chisari FV, Merlino G. Synergy between transforming growth factor alpha and Hepatitis B virus surface antigen in hepatocellular proliferation and carcinogenesis. Cancer Res 1997;57:3606-11.
13. Ito Y, Takeda T, Sakon M, Tsujimoto M, Tsujimoto M, Higashiyama S, Noda K, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J cancer 2001;84:1377-83.
14. Daveau M, Scotte M, Francois A, Coulouam C, Ros G, Tallet Y, et al. Hepatocyte growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog 2003;36:130-41.
15. Hopfner M, Sutter A, Huether A, Schuppan D, Zeitz M, Scherubl H. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol 2004;41:1008-16.
16. Huether A, Hopfner M, Sutter AP, Schuppan D, Scherubl H. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol 2005;43:661-9.
17. Matsuo M, Sakurai H, Saiki I. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Mol Cancer Ther 2003;2:557-61.
18. Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005;41:307-14.
19. Huether A, Hopfner M, Baradari V, Schuppan D, Scherubl H . EGFR blockage by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 2005;70:1568-78.
20. Philip PA, Mahoney MR, Allmer C. Phase II study of erlotinib in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23:6657-63.
21. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okinoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
22. Pao W, Miller VA. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005;23:3227-34.
23. Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small-cell lung cancer cell lines. Proc Natl Acad Sci USA 2005;102:3788-93.
24. Hirata A, Hosoi F, Miyagawa M, Ueda S, Naito S, Fujii T, et al. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res 2005;65:4253-60.
25. Chakravarti A, Loeffler J, Dyson N. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signalling. Cancer Res 2002;62:200-7.
26. Su MC, Lien HC, Jeng YM. Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma. Cancer Lett 2005;224:117-21.
27. Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoël MJ, Barbu V, Fartoux L, Poupon R, et al. Impact of IGF-IR/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer (sous presse).